Here are five things to know about the company’s third-quarter financials, according to an Oct. 24 news release:
1. Quarterly revenue grew 21% up from $3,949,530 in the same quarter last year.
2. Aurora saw net income of $71,120, for third-quarter 2024 compared to a loss of ($249,618) in the third quarter last year.
3. The nine-month period ending Sept. 30 saw a net loss of ($349,911) compared to a net loss of ($1,394,968) in the comparable period last year, a net improvement of $1,045,057.
4. Third-quarter sales of $4,767,121 increased by $687,578 or 16.8%,compared to Q2 2024’s $4,079,543 and was up 10.7% compared to the same periods in 2023.
5. Sales of Aurora’s SiLO-TFX SI joint implant and SiLO allograft implant made up 48.2%, or $2.3 million in sales, in the third quarter compared to 30.5% or $1.2 million in the same period the previous year. Sales increased 62.7% from Q1 2024 to Q3 2024.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
